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Summary
Background: Not all coronary events occur in young individuals with traditional risk factors. In recent years
some authors have observed increased prevalence of elevated anti-phospholipid (aPL) anti-
bodies in young patients with myocardial infarction. Also, thickening of the combined arterial
intima-media thickness (IMT) of superficial vessels has been identified as an independent risk
factor for both stroke and heart attack. The objective of our study was to assess possible associ-
ation between aPL antibodies and carotid IM thickening in young survivors of myocardial
infarction.
Material/Methods: In a case control study we determined IgG and IgM antiphospholipid antibodies by enzyme-
immunoassay, and IMT by ultrasonography in 50 male survivors of myocardial infarction
under the age of 50, and compared them to 50 healthy controls.
Results: Elevated aPL antibody levels (IgG>10 GPL; IgM>20MPL) were detected in 12 of 50 patients
(24%) with MI and in 3 of 50 controls (6%). The mean level of aPL antibodies was significantly
higher in the patients than in the controls (IgG 9.15±3.53 vs 7.69±2.98 GMP, p=0.04 and
IgM 18.46±7.61 vs 12.14±5.05 MPL, p<0.01). Patients with MI had a significantly greater
IMT than healthy controls (0.9 mm vs 0.6 mm; p<0.01). There was a correlation between aPL
and IM thickening (r=0.31; p=0.01). Among coronary risk factors only hypertension
(r=0.28; p=0.01) and smoking (r=0.41; p=0.01) showed a relationship with IMT.
Conclusion: The intima-media thickness of the carotid artery and elevated aPL antibodies are strongly
associated with the risk of myocardial infarction in young patients.
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BACKGROUND
Historically, atherosclerosis has been shown to be an
ancient disease that existed at least 3500 years ago in
Egypt and China. Today, we recognize that this arteri-
al pathology is ‘old’ in another way as well. Autopsy
studies have demonstrated that atherosclerosis begins
early in life, and is present for years, if not decades,
before clinical signs and symptoms occur. Despite this
indolent time course and the prolonged period of clin-
ical inactivity, the sequelae of atheroma, such as
myocardial infarction, unstable angina or stroke, usu-
ally occur suddenly. Ischemic cerebral and myocardial
events are the leading causes of adult mortality in most
developed countries, and account for at least 10 mil-
lion deaths per year [1]. Intravascular ultrasound stud-
ies have revealed widespread intimal thickening in
patients with atherosclerosis, and indeed in many
asymptomatic human adults [2–4]. B-mode ultrasound
carotid artery imaging is a noninvasive method that
can be used to visualize and measure the combined
thickness of the arterial intima and media (IMT) of
superficial vessels, where atherosclerosis originates
[5–7]. Median population values for IMT range
between 0.4 and 1.0 mm, while progression rates of
0.001 to 0.3 mm/y have been reported [8–12].
Thickening of the intima-media complex has been
identified as an independent risk factor for both stroke
and heart attack [13], while atherosclerosis is a risk fac-
tor for intima-media thickening. It has become
increasingly clear that not all coronary events occur in
individuals with traditional risk factors, and that in
some individuals isolated abnormalities of hemostasis
and thrombosis appear to play critical roles [14,15]. In
recent years, some authors have observed an increased
prevalence of elevated anti-phospholipid (aPL) anti-
body levels in young patients with myocardial infarc-
tion [16,17]. Furthermore, high titers of these antibod-
ies appear to serve as a marker of risk for recurrent
cardiovascular events [18]. Antibodies binding to
anionic phospholipids, such as cardiolipin, are associ-
ated with a clinical syndrome characterized in particu-
lar by venous and arterial thrombosis, recurrent abor-
tion, and thrombocytopenia [19]. Although the anti-
phospholipid (aPL) antibody syndrome was first
described in patients with systemic lupus erythemato-
sus (SLE), it is now generally accepted that there is a
group of patients in whom high titers of aPL antibod-
ies and thrombotic features occur without clinical man-
ifestations of SLE [20]. The purpose of the present
study, then, was to determine whether the presence of
aPL antibodies entails a risk of CAD, and whether
there is any relationship between aPL and carotid IM
thickening in young survivors of myocardial infarction.
MATERIAL AND METHODS
We examined 50 men (age£50; range 37 to 50; mean
45.7±3.58) who had experienced an MI at least six
months before the study. MI was diagnosed by clinical,
electrocardiographic, and enzymatic criteria. In 32
patients the diagnosis was additionally confirmed by
angiography. The control group consisted of 50 healthy
men (age£50, range 35-50, mean 44.2±3.75 years) who
had no history of CAD and completed an exercise stress
test with negative result. Coronary risk factors were
determined in both groups (table 1). Hypertension was
diagnosed if the blood pressure was >140/90 mmHg or
there was ongoing antihypertensive treatment. Cancer,
severe liver or kidney disease, and peptic ulcer were
exclusion criteria for this study. In all patients, IgG and
IgM antiphospholipid antibodies were detected by a
Age, mean±SD (min-max)
Intima-media thickness (mm; mean)
Intima-media thickness ≥0.1mm
IgG aCL antibodies (GPL; mean)
IgM aCL antibodies (MPL; mean)
aPL (IgG>10 GPL; IgM>20 MPL)
Carotid plaques (n)
Carotid stenosis >50% (n)
Obstruction of carotid arteries
Coronary risk factors:
Hypertension (n)
Cholesterol mmol/L (mean)
Triglicerides mmol/L (mean)
Smoking (n)
Diabetes(n)
Obesity (BMI >30) (n)
Positive family history (n)
Mean values and standard deviations (SD) are given for continuous variables, % and (n) for coronary risk factors;
*  P-values calculated by Mann-Whitney U test or Kolmogorov-Smirnov Two-Sample test;
**Chi-square test (Yates' correction)
45.7±3.58 (37–50)
0.9±0.02
25% (13)
9.15±3.53
18.45±7.61
24% (12)
24% (12)
4% (2)
0
19
6.09
2.37
44
5
10
25
44.2±3.75 (35–50)
0.6±0.01
4% (2)
7.68±2.98
12.13±5.05
6% (3)
2% (1)
0
0
9
5.39
1.97
30
0
9
23
NS*
<0.001*
0.001**
0.04*
<0.001*
<0.001**
0.01**
–
–
0.02**
0.01*
0.001*
0.01**
0.06**
NS**
NS**
Clinical data MI patients Control group p values
Table 1. Intima-media thickness (IMT), aPL antibodies and clinical characteristics of the subjects studied.
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standard ELISA technique (Sigma; Daco), as previously
described [21]. The results for aPL were expressed as
GPL or MPL-Units (GPL-U or MPL-U). Results above
10 GPL and 20 MPL were considered positive.
B-mode ultrasound quantification of carotid artery inti-
ma-media thickness was obtained in all patients
(Sequoia 512C sonograph; Acuson Corp, Mountainview,
USA; linear probe 6÷Hz). Intima-media thickness
(IMT) was measured in the left and right carotid arter-
ies and expressed as a mean of the maximum value in
the common carotid, bifurcation and internal carotid
artery (Fig. 1). Values in the range 1–1.3 mm were
regarded as indicative of IM thickening. Plaque was
defined as local IM thickening ≥1.3 mm. Carotid artery
stenosis was identified and quantified by analyzing the
Doppler velocity spectrum in combination with mea-
surement of the stenosis area in all patients with severe
lesions.
Statistical analysis
All statistical analyses were performed with the STA-
TISTICA data analysis software system, version 5
(StatSoft, Inc, Tulsa, Oklahoma, USA). The aPL anti-
body levels and IMT were compared between groups
using the Mann-Whitney U test (the Kolmogorov-
Smirnov Two-Sample test for mean values of age, total
cholesterol and triglycerides). IM thickening, elevated
aPL antibodies, carotid plaques, and other coronary
risk factors in patients and controls were compared
with the Yates’ corrected chi-square test. The non-
parametric Spearman R correlation test was applied to
analyze associations between aPL antibody levels, IMT
and classic risk factors. All results are expressed as
means ± standard deviation (SD). The significance
level was set at p<0.05.
RESULTS
Elevated aPL antibody levels (IgG >10 GPL; IgM >20
MPL) were detected in 12 of 50 patients with MI (24%)
and in 3 of 50 control subjects (6%); cf. Table 1. The dif-
ferences were statistically significant at the level of
p<0.001. The mean level of aPL antibodies was signifi-
cantly higher in patients with MI (the IgG mean was
9.15±3.53 GMP, the IgM mean was 18.46±7.61 MPL)
than in the control group (IgG mean 7.69±2.98 GMP,
p=0.04; IgM mean 12.14±5.05 MPL, p<0.01). The MI
patients had significantly greater carotid IMT than
healthy controls (mean 0.9±0.02mm vs 0.6±0.01mm;
p<0.01). IM thickening was detected in 13 cardiac
patients (25%) and only 2 controls (4%; p<0.001).
Carotid plaques were found in 12 MI patients (24%)
and in 1 control subject (2%, p<0.001). Stenosis exceed-
ing 50% of the carotid arteries was recorded in 2
patients (4%). None of the patients or healthy subjects
showed total obstruction of carotid arteries. There was a
correlation between IM thickening and aPL (r=0.31;
p=0.01). Among coronary risk factors only hyperten-
sion (r=0.28; p=0.01) and smoking (r=0.41; p=0.01)
correlated with IM thickening.
DISCUSSION
In the present study, elevated aCL antibody levels were
significantly more common in patients with MI than in
control subjects. Our data indicates that an elevated
level of aPL antibodies may carry an additional risk of
atherosclerosis, which supports previous observations
[22,23]. The association between aPL antibodies and
valvular lesions had been described previously in several
case reports and studies [24,25]. Some authors also sug-
gest that aPL antibodies contribute to the pathogenesis
of systemic and pulmonary hypertension [26]. Because
aPL antibodies in healthy subjects have been shown to
predict myocardial infarction [27], it is possible that at
Figure 1. Measurements of the intima-media thickness (IMT) of the common carotid artery (CCA) using ultrasonography (arrows). A. MI patient with
IM thickening. B. Healthy subject with normal IMT.
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least in some instances they could be directly involved in
the pathogenesis of thrombotic events.
Speculation on cause-and-effect based on statistical rela-
tionships is of course a highly questionable procedure.
However, in light of the accumulated experimental and
clinical data, this circumstantial evidence could be inter-
preted to support a role for aPL antibodies in throm-
binogenesis, rather than in the pathogenesis of athero-
sclerosis. Musia∏ et al. reported increased thrombino-
genesis in patients with antiphospholipid syndrome
[28,29]. In particular, the interactions between aPL anti-
bodies and smoking, leukocyte count, or triglycerides
support this conclusion, since all of these coronary risk
factors are known to be associated with hypercoagula-
tive stages [30–32]. Although the pathogenic mechanism
leading to thrombosis in patients with aPL remains
unclear, it is known that aPL can bind to endothelial
cells [33] and activate them [34,35]. Activated endotheli-
um may change its properties from antithrombotic
towards prothrombotic [36,37]. Another possibility is
impaired function of the protein C system [38], with an
important role played, among others, by acquired free
protein S deficiency. The most consistent finding in a
large number of studies reviewed by de Groot [39] is the
inhibition by antiphospholipid antibodies of the inacti-
vation of factor Va by activated protein C. Thus, an
important feedback mechanism inhibiting thrombin for-
mation could be impaired. The unopposed activity of
prothrombinase complex would then lead to increased
thrombin generation. Endothelium and other phospho-
lipid membranes may be involved. Antiphospholipid
antibodies can interfere with the activation of protein C
by the thrombomodulin-thrombin complex or by the
inhibition of the assembly of the protein C complex on
such surfaces.
Several different mechanisms have been proposed for
the involvement of aPL antibodies in thrombinogenesis
[40]. For example, aPL antibodies may bind not only to
the membranes of endothelial cells, but also to thrombo-
cytes. Infections may also play a role in the pathogenesis
of coronary heart disease [41]. A transient aPL antibody
response takes place in a variety of bacterial and viral
infections, and elevated levels can persist in many
chronic infections. Perhaps aCL antibodies rise in
response to chlamydial infection, which has been associ-
ated with coronary heart disease [42–44].
We have shown significant thickening of the intima-
media complex in patients with MI. Also, the number of
atherosclerotic plaques was greater in these patients in
comparison to healthy subjects. We observed a relation-
ship between aPL and IM thickening. Consistent with
other reports, we have shown that the IMT of the
carotid artery is strongly associated with the risk of car-
diovascular events [45,46]. Some authors have found a
significant correlation between IM thickening and sev-
eral cardiovascular risk factors, including age, hyperten-
sion, diabetes, total cholesterol, and smoking [47,48]. In
our study only hypertension and smoking correlated
with increased carotid IMT. Although the levels of total
cholesterol and triglycerides were significantly higher in
survivors of MI, they did not show such a relationship
with IMT. The effect of lipids on IMT may have been
masked by the absence of women and the relatively
young age of the study groups. Additionally, the patient
population distribution was highly skewed, and most of
these patients were on lipid-lowering treatment. B-
mode ultrasound carotid artery imaging is a noninva-
sive, safe and inexpensive method that can be used to
visualize and measure the combined arterial IMT of
superficial vessels [49]. This technique, which has been
proven to be reproducible in numerous studies (range
of absolute differences in replicate scans and readings
0.06–0.15 mm), yields information on atherosclerotic
wall changes that cannot be obtained by conventional
contrast angiography or MRI [49]. Increased carotid
IMT has been demonstrated to be predictive of ischemic
stroke and myocardial infarction [50–52]. Clinical trials
that have used carotid IMT as an endpoint in treatment
of asymptomatic subjects with known hypercholes-
terolemia or hypertension have shown that such treat-
ment reduces IMT progression rates and stabilizes or
regresses pre-existing atherosclerosis [53–55]. Carotid
IMT is a direct method of measuring the extent, severi-
ty and evolution of atherosclerosis, and helps to esti-
mate the efficacy of preventive medical treatment.
CONCLUSIONS
Our results indicate that measuring IMT and detecting
aPL antibodies can be used as a screening tool to identi-
fy asymptomatic subjects who are at risk of developing
atherosclerosis-related cardiovascular events.
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